Artificial Intelligence-Enabled Clinical Trials in Inflammatory Bowel Disease: Automating and Enhancing Disease Assessment and Study Management.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40158739.
- Also identified by DOI 10.1053/j.gastro.2025.02.039 and PMC identifier 12350071.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Artificial intelligence (AI) will fundamentally improve how we perform clinical trials by addressing issues of standardizing disease scoring, improving the sensitivity and precision of activity and phenotype assessments, and automating laborious and time-consuming study functions. Progress in AI image analysis is quickly proving to replicate expert judgment in endoscopy, histology, and cross-sectional imaging with speed, reproducibility, and reduced bias. However, AI analytics offer the ability to quantify disease characteristics with more detail and precision than human experts. Large language models and generative AI are automating the collection of high-quality data from electronic records and improving our ability to predict patient outcomes. This narrative review will focus on AI tools available today, their expected implementation, and future-facing opportunities for AI to reimagine inflammatory bowel disease clinical trials.
Medical subject headings
- Artificial Intelligence
- Inflammatory Bowel Diseases
- Clinical Trials as Topic